A world-first discovery could become a game-changer for patients at risk of rapid health deterioration, such as heart complications, stroke, sepsis and cancer. Researchers developed an antibody as a biosensor, to continuously monitor rapid changes in the concentration of EGFR, a protein present on cancer cells and in body fluids.